Capricor Therapeutics (CAPR) Stock Climbs On COVID-19 Survival

Capricor Therapeutics CAPR Stock News

Capricor Therapeutics Inc (NASDAQ: CAPR) is running for the top, gaining in multiples this morning. The gains come after the company reported that COVID-19 patients treated with its experimental drug experienced a 100% survival rate. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

COVID-19 Survival Rate Sends CAPR Stock Through The Roof

In the press release, Capricor Therapeutics provided new data surrounding CAP-1002. CAP-1002 is the company’s lead asset and cardiac cell therapy candidate.

According to the release, the treatment led to a 100% survival rate in patients with critical symptoms of COVID-19. The data came from the Cedars-Sinai Medical Center and was part of six compassionate care cases.

CAPR said that all six critically ill COVID-19 patients suffered from ARDS. Five of these patients were on mechanical ventilatory support. All of these patients were safely treated with CAP-1002.

The company said that of the six treated patients, four have already been discharged. As a result of the positive data, the FDA has approved the company’s request to treat up to 20 additional patients under the expanded access protocol

The company also said that it is a planning randomized, placebo-controlled trial to treat patients with moderate to severe COVID-19. This trial is expected to be funded by non-equity capital.

In a statement, Dr. Linda Marban, Ph.D., CEO at CAPR, had the following to offer:

As the global medical community continues to come together in its battle against COVID-19, the results of our initial compassionate care cases are extremely promising and what we had anticipated. We look forward to continuing to treat additional patients under our recently approved expanded access program Investigational New Drug application. CAP-1002 is an easy-to-deliver intravenous therapy that has been administered successfully to over 150 patients to date. Given its novel mechanism of action, it could be a potential game-changer in helping countless COVID-19 patients.

This News Is Massive

We all know that COVID-19 is a horrible thing. The pandemic has changed the way of life for people around the world. So, we want to put an end to it.

Of course, to put an end to the pandemic, we need testing, we need vaccines, and we need treatments for those who are sick. While several companies have announced that they are working on treatement options, there are only a handful that have anything tangible to show for their work. Capricor is one of these.

Looking further, there have only been a couple of companies that have reported data from treatments provided to actual COVID-19 patients. Gilead Sciences (GILD) reported data today showing that its COVID-19 treatment had positive results. But the goal in these patients was to get to a 50% response. CAPR generated a 100% response rate, with benefits in some of the sickest of COVID-19 patients.

As far as I’m considered, CAPR is in the lead in the race to develop a strong treatment option for COVID-19 patients, and that’s overwhelmingly valuable. So, this stock is hard to ignore.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.